Fennec Pharmaceuticals Inc. (TSE:FRX) to Post Q2 2024 Earnings of ($0.21) Per Share, Capital One Financial Forecasts

Fennec Pharmaceuticals Inc. (TSE:FRXFree Report) – Equities researchers at Capital One Financial cut their Q2 2024 EPS estimates for shares of Fennec Pharmaceuticals in a report released on Monday, June 10th. Capital One Financial analyst N. Quibria now forecasts that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter, down from their previous estimate of ($0.19). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $1.20 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at $0.07 EPS, FY2025 earnings at $0.35 EPS, FY2027 earnings at $1.75 EPS and FY2028 earnings at $3.53 EPS.

Fennec Pharmaceuticals (TSE:FRXGet Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.67 by C($0.11). Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. The firm had revenue of C$34.21 million during the quarter, compared to analyst estimates of C$14.19 million.

Fennec Pharmaceuticals Stock Performance

TSE FRX opened at C$9.44 on Wednesday. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 6.93 and a quick ratio of 10.17. The company has a market cap of C$257.90 million, a P/E ratio of 188.80 and a beta of 0.46. The stock has a 50-day moving average of C$11.59 and a two-hundred day moving average of C$12.84. Fennec Pharmaceuticals has a 1-year low of C$9.00 and a 1-year high of C$15.43.

Insider Activity

In other Fennec Pharmaceuticals news, Senior Officer Adrian J. Haigh bought 22,222 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were purchased at an average cost of C$2.31 per share, with a total value of C$51,332.82. In related news, Senior Officer Adrian J. Haigh purchased 22,222 shares of the business’s stock in a transaction on Monday, April 15th. The shares were bought at an average price of C$2.31 per share, for a total transaction of C$51,332.82. Also, Senior Officer Robert Christopher Andrade sold 13,975 shares of the business’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of C$10.90, for a total value of C$152,345.67. Over the last quarter, insiders sold 39,112 shares of company stock valued at $390,926. 17.27% of the stock is currently owned by company insiders.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Featured Stories

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.